PeptideLabs Logo
PeptideLabs
All profiles

Liraglutide

Peptide · Metabolism & GLP-1

Enhances glucose-dependent insulin signalling and influences satiety and glucagon release.

Approved for specific uses
LibraryNo account · this device only

Also known as: GLP-1 · Victoza · Saxenda

Use at a glance

Liraglutide

Enhances glucose-dependent insulin signalling and influences satiety and glucagon release.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Medicine instructions · named product only

Product or source: Liraglutide · SAXENDA

What amount?
0.6 mg
How often?
once per day
What time of day?
Time of day not stated here
What period?
Week 1
How is it used?
The named medicines are ready-made injectable solutions. Their instructions and device are product-specific.
Does it need mixing?
No. The named ready-made solutions are not mixed with water. A research powder is a different product.
View preparationCheck sources
Overview of all entries

  • Liraglutide · Week 1

    Medicine instructions · named product only · SAXENDA

    0.6 mg · once per day · Time of day not stated here

  • Liraglutide · Week 2

    Medicine instructions · named product only · SAXENDA

    1.2 mg · once per day · Time of day not stated here

  • Liraglutide · Week 3

    Medicine instructions · named product only · SAXENDA

    1.8 mg · once per day · Time of day not stated here

  • Liraglutide · Week 4

    Medicine instructions · named product only · SAXENDA

    2.4 mg · once per day · Time of day not stated here

  • Liraglutide · Week 5+

    Medicine instructions · named product only · SAXENDA

    3 mg · once per day · Time of day not stated here

More factsPeptide · Metabolism & GLP-1
Classification
Peptide · Metabolism & GLP-1
Research focus
Enhances glucose-dependent insulin signalling and influences satiety and glucagon release.
Evidence
Established
Status
Approved for specific uses

Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.

Schedule explained in detailApproved medicine

Amount status

Victoza label: 0.6 mg daily for at least one week, then 1.2 mg and, if needed, 1.8 mg. Saxenda label: 0.6 →1.2 →1.8 →2.4 →3 mg daily in weekly steps. Do not mix indications.

Profile evidence level: established.

Timing

Once daily per the prescribing information of the respective prefilled pen.

No individual recommendation.

Cycle/duration

Long-term treatment with product- and indication-specific discontinuation/efficacy criteria; no community cycle.

No individual recommendation.

Mixing & calculations

No. The named ready-made solutions are not mixed with water. A research powder is a different product.

All preparation informationProduct details and calculation examples from the available sources.

Victoza and Saxenda are prefilled pens; no reconstitution and no generic U-100 table. The reference source currently provides no complete protocol.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

GLP-1 receptor agonist

Liraglutide is classified as “GLP-1 receptor agonist”. Enhances glucose-dependent insulin signalling and influences satiety and glucagon release. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

GLP-1 receptor activation

Researchers study how activating the GLP-1 receptor affects fullness, stomach emptying, and insulin release after a meal. They typically measure blood sugar curves, body weight, and food intake over time, similar to tracking how quickly someone feels hungry again after eating.

02

Blood sugar and appetite outcomes

Researchers study how a substance changes blood sugar levels and feelings of hunger over the course of a day, similar to tracking how full someone feels after different meals. Typical measures include blood glucose readings and questionnaires about hunger and food intake.

03

Gastric emptying

This examines how quickly food leaves the stomach and enters the intestine, a process that influences how full someone feels after eating. Emptying speed is typically measured using imaging or breath tests, similar to timing how long a meal takes to move through the digestive system.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Weight management forums

In these forums, users compare their own weight trajectories, side effects, and perceived appetite changes between different products. Before-and-after photos and personal timelines are often shared. Such anecdotes and vendor marketing claims are not scientific proof of efficacy.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

General wellness forums

Broader wellbeing impressions such as mood, sleep, and general feeling after using various products are exchanged here, usually without structured tracking. Such general impressions are not a substitute for targeted clinical examination.

Adverse effects and safety risks

  • Gastrointestinal effects, dehydration, and changes in glucose or appetite may occur depending on the target; incretin medicines can also carry gallbladder, pancreatic and retinopathy warnings.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Pregnancy, severe gastric-emptying disorders, and relevant pancreatic, gallbladder, renal or endocrine disease require professional assessment; the exact label may add contraindications.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Depending on substance and indication, weight, blood pressure, hydration, glucose/HbA1c, kidney and liver markers, and concomitant medicines may be reviewed; symptoms guide further tests.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Established

Long-standing clinical data exist, but they do not automatically transfer to newer agents.

Clinical evidence

The described biological role is well established, or extensive regulator-reviewed human data exist for clearly defined products and uses. This does not automatically transfer to other products or purposes.

Liraglutide is an older GLP-1 agonist with a shorter activity profile than semaglutide or dulaglutide.

Storage and stability

  • Store unopened pens per the label at 2–8 °C and do not freeze.
  • Once opened, pens are typically kept for up to 30 days refrigerated or up to 30 °C depending on the product; always check the specific label.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Approved for specific uses

Prescription active ingredient for defined indications in at least one jurisdiction; not offered here.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile